## Abstract 2′‐Deoxy‐2′‐[^18^F]fluoro‐5‐substituted‐1‐__β__‐D‐arabinofuranosyluracils, including 2′‐deoxy‐2′‐[^18^F]fluoro‐5‐methyl‐1‐__β__‐D‐arabinofuranosyluracil [^18^F]FMAU and [^18^F]FEAU are established radiolabeled probes to monitor cellular proliferation and herpes simplex virus type 1 thym
Radiosynthesis of 4-[18F]fluoromethyl-L-phenylalanine and [18F]FET via a same strategy and automated synthesis module
✍ Scribed by Ken Kersemans; John Mertens; Vicky Caveliers
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- French
- Weight
- 198 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Currently there is still a need for more potent amino acid analogues as tumour imaging agents for peripheral tumour imaging with PET as it was recently reported that the success of O‐(2′‐[^18^F]fluoroethyl)‐L‐tyrosine ([^18^F]FET) is limited to brain, head and neck tumours. As the earlier described 2‐Amino‐3‐(2‐[^18^F]fluoromethyl‐phenyl)‐propionic acid (2‐[^18^F]FMP) suffered from intramolecular‐catalysed defluorination, we synthesized 2‐Amino‐3‐(4‐[^18^F]fluoromethyl‐phenyl)‐propionic acid (4‐[^18^F]FMP) as an alternative for tumour imaging with PET. Radiosynthesis of 4‐[^18^F]FMP, based on Br for [^18^F] aliphatic nucleophilic exchange, was performed with a customized modular Scintomics automatic synthesis hot__box__^three^ system in a high overall yield of 30% and with a radiochemical purity of \gt 99%. 4‐[^18^F]FMP was found to be stable in its radiopharmaceutical formulation, even at high radioactivity concentrations. Additionally, for a comparative study, [^18^F]FET was synthesized using the same setup in 40% overall yield, with a radiochemical purity \gt 99%. The described automated radiosynthesis allows the production of two different amino acid analogues with minor alternations to the parameter settings of the automated system, rendering this unit versatile for both research and clinical practice. Copyright © 2009 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract The synthesis of 1‐(5‐chloro‐2‐{2‐[(2R)‐4‐(4‐[^18^F]fluorobenzyl)‐2‐methylpiperazin‐1‐yl]‐2‐oxoethoxy}phenyl)urea (**[^18^F]4**), a potent nonpeptide CCR1 antagonist, is described as a module‐assisted two‐step one‐pot procedure. The final product was obtained utilizing the reductive ami